JP2022512882A5 - - Google Patents

Info

Publication number
JP2022512882A5
JP2022512882A5 JP2021523715A JP2021523715A JP2022512882A5 JP 2022512882 A5 JP2022512882 A5 JP 2022512882A5 JP 2021523715 A JP2021523715 A JP 2021523715A JP 2021523715 A JP2021523715 A JP 2021523715A JP 2022512882 A5 JP2022512882 A5 JP 2022512882A5
Authority
JP
Japan
Prior art keywords
manipulated
population
cells
sequence
gene
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2021523715A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022512882A (ja
JP7553440B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/IB2019/001194 external-priority patent/WO2020095107A1/en
Publication of JP2022512882A publication Critical patent/JP2022512882A/ja
Publication of JP2022512882A5 publication Critical patent/JP2022512882A5/ja
Application granted granted Critical
Publication of JP7553440B2 publication Critical patent/JP7553440B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2021523715A 2018-11-07 2019-11-07 抗ｃｄ３３免疫細胞癌療法 Active JP7553440B2 (ja)

Applications Claiming Priority (11)

Application Number Priority Date Filing Date Title
US201862756718P 2018-11-07 2018-11-07
US62/756,718 2018-11-07
US201862767388P 2018-11-14 2018-11-14
US201862767395P 2018-11-14 2018-11-14
US62/767,388 2018-11-14
US62/767,395 2018-11-14
US201962826643P 2019-03-29 2019-03-29
US201962826648P 2019-03-29 2019-03-29
US62/826,648 2019-03-29
US62/826,643 2019-03-29
PCT/IB2019/001194 WO2020095107A1 (en) 2018-11-07 2019-11-07 Anti-cd33 immune cell cancer therapy

Publications (3)

Publication Number Publication Date
JP2022512882A JP2022512882A (ja) 2022-02-07
JP2022512882A5 true JP2022512882A5 (https=) 2022-11-15
JP7553440B2 JP7553440B2 (ja) 2024-09-18

Family

ID=69159803

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021523715A Active JP7553440B2 (ja) 2018-11-07 2019-11-07 抗ｃｄ３３免疫細胞癌療法

Country Status (12)

Country Link
US (1) US20220226375A1 (https=)
EP (1) EP3877414A1 (https=)
JP (1) JP7553440B2 (https=)
KR (1) KR20210089712A (https=)
CN (1) CN113227141A (https=)
AU (1) AU2019377892A1 (https=)
BR (1) BR112021008041A2 (https=)
CA (1) CA3118816A1 (https=)
IL (1) IL282286A (https=)
MX (1) MX2021005398A (https=)
SG (1) SG11202103832SA (https=)
WO (1) WO2020095107A1 (https=)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2019130504A (ru) 2017-02-28 2021-03-30 Вор Байофарма, Инк. Композиции и способы ингибирования линиеспецифических белков
EA202092044A1 (ru) * 2018-03-14 2021-03-03 Дзе Юнайтед Стейтс Оф Америка, Эз Репрезентед Бай Дзе Секретари, Департмент Оф Хелс Энд Хьюман Сёрвисез Химерные рецепторы антигена против cd33 и их применения
CA3110837A1 (en) 2018-08-28 2020-03-05 Vor Biopharma Inc. Genetically engineered hematopoietic stem cells and uses thereof
AU2020280103A1 (en) * 2019-05-23 2021-12-23 Vor Biopharma Inc. Compositions and methods for CD33 modification
WO2020261219A1 (en) 2019-06-27 2020-12-30 Crispr Therapeutics Ag Use of chimeric antigen receptor t cells and nk cell inhibitors for treating cancer
KR20220051401A (ko) 2019-09-06 2022-04-26 크리스퍼 테라퓨틱스 아게 배양 중 개선된 지속성을 갖는 유전적으로 조작된 t 세포
CN116322716A (zh) 2020-09-23 2023-06-23 克里斯珀医疗股份公司 Regnase-1和/或TGFBRII被破坏的基因工程化T细胞具有改善的功能性和持久性
MX2023004811A (es) * 2020-10-26 2023-06-29 Res Institute At Nationwide Children´S Hospital Células nk del receptor de antígeno quimérico (car) y usos de las mismas.
WO2022137181A1 (en) 2020-12-23 2022-06-30 Crispr Therapeutics Ag Co-use of lenalidomide with car-t cells
EP4305153A1 (en) 2021-03-09 2024-01-17 CRISPR Therapeutics AG Genetically engineered t cells with ptpn2 knockout have improved functionality and anti-tumor activity
US20230346836A1 (en) 2021-12-22 2023-11-02 Crispr Therapeutics Ag Genetically engineered t cells with disrupted casitas b-lineage lymphoma proto-oncogene-b (cblb) and uses thereof
WO2024023801A2 (en) 2022-07-29 2024-02-01 Crispr Therapeutics Ag Genetically engineered immune cells having disrupted transporter associated with antigen processing-1 (tap-1) gene
WO2024023802A2 (en) 2022-07-29 2024-02-01 Crispr Therapeutics Ag Genetically engineered immune cells having disrupted transporter associated with antigen processing-2 (tap-2) gene
WO2024023804A2 (en) 2022-07-29 2024-02-01 Crispr Therapeutics Ag Genetically engineered immune cells having disrupted transporter associated with antigen processing binding protein (tapbp) gene
WO2024192108A1 (en) 2023-03-14 2024-09-19 Evolveimmune Therapeutics, Inc. Genetically modified car t cells and methods of making and using the same

Family Cites Families (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6352694B1 (en) 1994-06-03 2002-03-05 Genetics Institute, Inc. Methods for inducing a population of T cells to proliferate using agents which recognize TCR/CD3 and ligands which stimulate an accessory molecule on the surface of the T cells
US6534055B1 (en) 1988-11-23 2003-03-18 Genetics Institute, Inc. Methods for selectively stimulating proliferation of T cells
US6905680B2 (en) 1988-11-23 2005-06-14 Genetics Institute, Inc. Methods of treating HIV infected subjects
US5858358A (en) 1992-04-07 1999-01-12 The United States Of America As Represented By The Secretary Of The Navy Methods for selectively stimulating proliferation of T cells
US7175843B2 (en) 1994-06-03 2007-02-13 Genetics Institute, Llc Methods for selectively stimulating proliferation of T cells
US5773001A (en) 1994-06-03 1998-06-30 American Cyanamid Company Conjugates of methyltrithio antitumor agents and intermediates for their synthesis
US7067318B2 (en) 1995-06-07 2006-06-27 The Regents Of The University Of Michigan Methods for transfecting T cells
US6692964B1 (en) 1995-05-04 2004-02-17 The United States Of America As Represented By The Secretary Of The Navy Methods for transfecting T cells
GB9710809D0 (en) 1997-05-23 1997-07-23 Medical Res Council Nucleic acid binding proteins
GB9710807D0 (en) 1997-05-23 1997-07-23 Medical Res Council Nucleic acid binding proteins
US6140081A (en) 1998-10-16 2000-10-31 The Scripps Research Institute Zinc finger binding domains for GNN
US6453242B1 (en) 1999-01-12 2002-09-17 Sangamo Biosciences, Inc. Selection of sites for targeting by zinc finger proteins and methods of designing zinc finger proteins to bind to preselected sites
US6534261B1 (en) 1999-01-12 2003-03-18 Sangamo Biosciences, Inc. Regulation of endogenous gene expression in cells using zinc finger proteins
US6867041B2 (en) 2000-02-24 2005-03-15 Xcyte Therapies, Inc. Simultaneous stimulation and concentration of cells
US6797514B2 (en) 2000-02-24 2004-09-28 Xcyte Therapies, Inc. Simultaneous stimulation and concentration of cells
KR20030032922A (ko) 2000-02-24 2003-04-26 싸이트 테라피스 인코포레이티드 세포의 동시 자극 및 농축
JP2002060786A (ja) 2000-08-23 2002-02-26 Kao Corp 硬質表面用殺菌防汚剤
JP2005500061A (ja) 2001-08-20 2005-01-06 ザ スクリップス リサーチ インスティテュート Ｃｎｎについての亜鉛フィンガー結合ドメイン
ZA200503075B (en) * 2002-11-07 2006-09-27 Immunogen Inc Anti-CD33 antibodies and method for treatment of acute myeloid leukemia using the same
US7888121B2 (en) 2003-08-08 2011-02-15 Sangamo Biosciences, Inc. Methods and compositions for targeted cleavage and recombination
US7972854B2 (en) 2004-02-05 2011-07-05 Sangamo Biosciences, Inc. Methods and compositions for targeted cleavage and recombination
WO2011072246A2 (en) 2009-12-10 2011-06-16 Regents Of The University Of Minnesota Tal effector-mediated dna modification
WO2013026839A1 (en) * 2011-08-23 2013-02-28 Roche Glycart Ag Bispecific antibodies specific for t-cell activating antigens and a tumor antigen and methods of use
WO2013026837A1 (en) * 2011-08-23 2013-02-28 Roche Glycart Ag Bispecific t cell activating antigen binding molecules
US20130309223A1 (en) * 2012-05-18 2013-11-21 Seattle Genetics, Inc. CD33 Antibodies And Use Of Same To Treat Cancer
EP2961773B1 (en) 2013-02-26 2019-03-20 Roche Glycart AG Bispecific t cell activating antigen binding molecules
AU2014248640B2 (en) 2013-03-13 2018-03-01 Seagen Inc. Cyclodextrin and antibody-drug conjugate formulations
JP6681837B2 (ja) * 2014-03-11 2020-04-15 セレクティスＣｅｌｌｅｃｔｉｓ 同種移植に適合するｔ細胞を作製するための方法
CN106795221B (zh) * 2014-04-03 2022-06-07 塞勒克提斯公司 用于癌症免疫治疗的cd33特异性嵌合抗原受体
TWI719942B (zh) * 2014-07-21 2021-03-01 瑞士商諾華公司 使用ｃｄ３３嵌合抗原受體治療癌症
US20170335331A1 (en) 2014-10-31 2017-11-23 The Trustees Of The University Of Pennsylvania Altering Gene Expression in CART Cells and Uses Thereof
JP2018509148A (ja) * 2015-03-11 2018-04-05 セレクティスＣｅｌｌｅｃｔｉｓ 患者における持続性および／または生着を増加させるために同種ｔ細胞を改変する方法
WO2017025323A1 (en) * 2015-08-11 2017-02-16 Cellectis Cells for immunotherapy engineered for targeting cd38 antigen and for cd38 gene inactivation
AU2016337525B2 (en) 2015-10-16 2022-01-20 The Trustees Of Columbia University In The City Of New York Compositions and methods for inhibition of lineage specific antigens
WO2018073393A2 (en) * 2016-10-19 2018-04-26 Cellectis Tal-effector nuclease (talen) -modified allogenic cells suitable for therapy
EP3548055A4 (en) * 2016-12-02 2020-08-19 University of Southern California SYNTHETIC IMMUNE RECEPTORS AND THEIR PROCESSES FOR USE
SG11201907638QA (en) 2017-02-20 2019-09-27 Dragonfly Therapeutics Inc Proteins binding cd33, nkg2d and cd16
CN107746831B (zh) 2017-11-07 2019-04-23 南京北恒生物科技有限公司 具有化疗药物抗性的通用型cart/tcrt细胞及其构建方法

Similar Documents

Publication Publication Date Title
JP2022512882A5 (https=)
JP2021522820A5 (https=)
JP2022513586A5 (https=)
CN114585645B (zh) 对杂合性丧失作出响应的细胞表面受体
CN107709548B (zh) 用于增强治疗性免疫细胞的功效的方法
CN112390892B (zh) 一种嵌合抗原受体以及表达该嵌抗原受体的免疫效应细胞
JP2021531004A5 (https=)
JP2022509017A5 (https=)
JP2023542348A5 (https=)
JP2016514462A5 (https=)
JP2021525524A5 (https=)
KR102859548B1 (ko) 메소텔린 양성 암을 치료하기 위한 조성물 및 방법
JP2018508215A5 (https=)
JP2021503006A5 (https=)
JP2018536436A5 (https=)
US20170081411A1 (en) Regulatable chimeric antigen receptor
JP2023514407A5 (https=)
JP2017500869A5 (https=)
KR102859550B1 (ko) Ceacam 양성 암을 치료하기 위한 조성물 및 방법
AU2016382512A1 (en) Immune effector cell therapies with enhanced efficacy
CN107735407A (zh) 治疗剂
JP2024097924A (ja) 抗ｐｔｋ７免疫細胞癌療法
CN115916833B (zh) 靶向b7h3的抗原结合多肽及其应用
CN107106670A (zh) 用于修饰的t细胞的方法和组合物
JP2024097924A5 (https=)